MergerApr 29, 2026, 05:02 PM
ENZN: Merger with Viskase Companies, Inc.; Name Change; 1-for-100 Reverse Split
AI Summary
Viskase Holdings, Inc. (formerly Enzon Pharmaceuticals, Inc.) filed an Amendment No. 1 to its 2025 Annual Report on Form 10-K/A to include Part III information. The filing details the merger with Viskase Companies, Inc. on March 26, 2026, a subsequent name change, and a 1-for-100 reverse stock split. It also outlines significant changes to the board of directors and executive officers post-merger, along with compensation details and beneficial ownership information.
Key Highlights
- Enzon Pharmaceuticals, Inc. merged with Viskase Companies, Inc. on March 26, 2026.
- Company name changed to Viskase Holdings, Inc. following the merger.
- Effected a 1-for-100 reverse stock split prior to the merger.
- Post-merger, board changed to 5 directors; 3 directors and CEO resigned.
- Carl C. Icahn and affiliated entities beneficially own 93.7% of common stock.
- CEO Richard L. Feinstein's 2025 compensation was $232,678.
- Randolph C. Read received $239,444 in director compensation for 2025.
- Total auditor fees for EisnerAmper LLP were $187,275 in 2025.